ImmUniverse prospective clinical study has started: first patients enrolled

To advance the understanding of the molecular mechanisms underlying the two diseases under study in the project, ulcerative colitis (UC) and atopic dermatitis (AD), a prospective observational study complements the inclusion of retrospective cohorts. The observational cohort will in total include 270 UC patients at the clinical sites of Christian-Albrechts-Universität zu Kiel (CAU), Amsterdam UMC, Katholieke Universiteit Leuven and Centre Hospitalier Régional Universitaire Nancy as well as 300 AD patients at the clinical sites of Christian-Albrechts-Universität zu Kiel, Ludwig-Maximilian University, Aarhus University Hospital and Radboud University Medical Center.

With the inclusion of the first two patients, one for UC and one for AD by the work package leader CAU the study has now officially kicked off and sample analysis will soon start to provide multi-Omics datasets consisting of tissue and blood transcriptomes, DNA methylomes, fecal and skin microbiome, serum metabolomics / lipidomics, multidimensional immunophenotyping and exosome miRINA profiles to identify tissue specific and circulating disease signatures in AD and UC.